Literature DB >> 15911103

P2Y purinergic receptors regulate the growth of human melanomas.

Nicholas White1, Mina Ryten, Elizabeth Clayton, Peter Butler, Geoffrey Burnstock.   

Abstract

Adenosine 5'-triphosphate is known to function as a potent extracellular messenger producing its effects via a distinct family of cell surface receptors. Different receptor subtypes have been shown to modulate different cellular functions such as proliferation, differentiation and apoptosis. We investigated the functional expression and proliferative action of metabotropic P2Y receptors in human melanoma tissue and cells. Expression of functional P2Y1, P2Y2 and P2Y6 receptor subtypes was established by reverse transcriptase polymerase chain reaction, immunohistochemistry and intracellular calcium measurements using a Fluorometric Imaging Plate Reader. Incubation of A375 melanoma cells with the P2Y1 receptor-selective agonist 2-methylthioadenosine-5-diphosphate caused a decrease in cell number which was dose-dependent, whereas incubation with the P2Y2 receptor agonist uridine triphosphate caused a dose-dependent increase in cell number. The action of extracellular nucleotides on P2Y receptors was shown to mediate the growth of melanomas and the P2Y1 receptor is a putative target for melanoma therapy.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15911103     DOI: 10.1016/j.canlet.2004.11.027

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  25 in total

1.  Activation of the P2Y1 receptor induces apoptosis and inhibits proliferation of prostate cancer cells.

Authors:  Qiang Wei; Stefano Costanzi; Qiu-Zhen Liu; Zhan-Guo Gao; Kenneth A Jacobson
Journal:  Biochem Pharmacol       Date:  2011-05-23       Impact factor: 5.858

2.  Platelet count as a predictor of metastasis and venous thromboembolism in patients with cancer.

Authors:  Joanna L Sylman; Annachiara Mitrugno; Garth W Tormoen; Todd H Wagner; Parag Mallick; Owen J T McCarty
Journal:  Converg Sci Phys Oncol       Date:  2017-05-17

Review 3.  Expression and function of P2 receptors in hematopoietic stem and progenitor cells.

Authors:  Wenli Feng; Lina Wang; Guoguang Zheng
Journal:  Stem Cell Investig       Date:  2015-07-30

4.  Altered purinergic receptor-Ca²⁺ signaling associated with hypoxia-induced epithelial-mesenchymal transition in breast cancer cells.

Authors:  Iman Azimi; Hannah Beilby; Felicity M Davis; Daneth L Marcial; Paraic A Kenny; Erik W Thompson; Sarah J Roberts-Thomson; Gregory R Monteith
Journal:  Mol Oncol       Date:  2015-09-25       Impact factor: 6.603

Review 5.  Purinergic signalling and cancer.

Authors:  Geoffrey Burnstock; Francesco Di Virgilio
Journal:  Purinergic Signal       Date:  2013-12       Impact factor: 3.765

Review 6.  Pathophysiology of astroglial purinergic signalling.

Authors:  Heike Franke; Alexei Verkhratsky; Geoffrey Burnstock; Peter Illes
Journal:  Purinergic Signal       Date:  2012-05-01       Impact factor: 3.765

7.  Transformation by a nucleotide-activated P2Y receptor is mediated by activation of Galphai, Galphaq and Rho-dependent signaling pathways.

Authors:  Anurag Singh; José L Boyer; Channing J Der; Irene E Zohn
Journal:  J Mol Signal       Date:  2010-07-23

Review 8.  Extracellular ATP and cancer: an overview with special reference to P2 purinergic receptors.

Authors:  Tamás Deli; László Csernoch
Journal:  Pathol Oncol Res       Date:  2008-06-25       Impact factor: 3.201

9.  An in vivo model of melanoma: treatment with ATP.

Authors:  Nicholas White; Gillian E Knight; Peter E M Butler; Geoffrey Burnstock
Journal:  Purinergic Signal       Date:  2009-04-04       Impact factor: 3.765

Review 10.  Short- and long-term (trophic) purinergic signalling.

Authors:  Geoffrey Burnstock
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2016-08-05       Impact factor: 6.237

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.